Yongliang Tong

机构：Shanghai Medical College of Fudan University, Fudan University, Institute of Process Engineering · ORCID：0000-0002-5383-1161

发表论文 33 篇 · 总被引 224 次 · h-index 8

代表论文

• PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way (2022 · Journal for ImmunoTherapy of Cancer · 被引 67)
• New laboratory evidence for the association between endothelial dysfunction and COVID‐19 disease progression (2022 · Journal of Medical Virology · 被引 28)
• Different Immunoregulation Roles of Activin A Compared With TGF-β (2022 · Frontiers in Immunology · 被引 24)
• A nanobody-enzyme fusion protein targeting PD-L1 and sialic acid exerts anti-tumor effects by C-type lectin pathway-mediated tumor associated macrophages repolarizing (2025 · International Journal of Biological Macromolecules · 被引 16)
• Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner (2022 · Cancer Immunology Research · 被引 16)
• Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy (2022 · Frontiers in Immunology · 被引 13)